Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
57%(4 trials)

Phase Distribution

Ph phase_1
1
14%
Ph phase_3
1
14%
Ph phase_2
5
71%

Phase Distribution

1

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 25 (71.4%)
Phase 31 (14.3%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

NCT04532931
completedphase_1

Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate

NCT01523002
completedphase_2

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

NCT00331136
completedphase_2

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

NCT01594931
completedphase_2

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

NCT04475107
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04532931Phase 2

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Completed
NCT01523002Phase 1

Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate

Completed
NCT00331136Phase 2

Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria

Completed
NCT01594931Phase 2

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

Completed
NCT04475107Phase 2

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Completed
NCT02389439Phase 2

Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria

Completed
NCT02411994Phase 3

Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7